AstraZeneca lung cancer drug approved for new dosing regimen in EU, UK
mfinzi had been approved in Europe and Britain for a spaced-out, fixed-dose regimen for a common type of lung cancer
FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London, April 28, 2014. REUTERS/Stefan Wermuth/File Photo
British drugmaker AstraZeneca said on Friday that its cancer drug Imfinzi had been approved in Europe and Britain for a spaced-out, fixed-dose regimen for a common type of lung cancer, to help reduce the frequency of hospital visits.
The company said that an additional dosing option of a 1,500mg fixed dose every four weeks was approved for use in adults with advanced non-small cell lung cancer where tumours cannot be surgically removed.
Keep updated, follow The Business Standard's Google news channel
